U.S. Department of Health and Human Services
Indian Health Service: The Federal Health Program for American Indians and Alaska Natives
A - Z Index:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

California Area Office logoCalifornia Area Office

Email From IHS CMO Dr. Susan Karol - Nationwide Shortage of TST antigen solutions

 

An Adobe PDF version of the following email message is available for download here: PDF (213KB)


From: Karol, Susan (IHS/HQ)
Sent: Wednesday, September 18, 2013 7:55 PM
To: NCCMO Group; LISTSERV-IHS National Council Of Clinical Directors; Pattea, Sandra D (IHS/HQ)
Cc: Bartholomew, Michael (IHS/HQ); IHS Area Directors
Subject: FW: Nationwide Shortage of TST antigen solutions-please forward to providers across our system.

Good Day to all,

Please review and forward onto other providers  in your areas and service units.

On September 4, 2013, the Centers for Disease Control and Prevention (CDC) released recommendations for patient care and public health practice during the continued nationwide shortage of tuberculin skin test (TST) antigen solutions[i]

During this period of TST antigen solutions shortage, the CDC recommends 3 general approaches:

  1. Substitute the interferon-γ release assay (IGRA) blood tests, (QuantiFERON-TB Gold In Tube® and TSpot TB®) blood tests for TSTs.
  2. Substitute APLISOL® for TUBERSOL® for skin testing if APLISOL® is available.
  3. Allocate TSTS to priority usages, such as tuberculosis (TB) contact investigations; priorities can be set in accordance to relative TB risks. A priority strategy might require deferment of testing.

Recommendations published by CDC in 2000 discourage routine TST screening for persons at low risk for TB[ii].

American Indian and Alaska Native people continue to be at high risk for TB infection.

Despite continued decreases in incidence over the past decade, the incidence of TB disease remains seven times that of Non-Hispanic Whites[iii]

Prior, routine TST screening programs in Indian Country identified many of those with latent TB infection (LTBI). Since 2000, targeted testing of those at high risk, such as persons with diabetes, has been performed in IHS and Tribal facilities. Yet, despite the fact that TB is more likely to progress among persons with diabetes and at a faster rate, many of those with diabetes either have not been tested or have not completed treatment for LTBI.

With the ongoing shortage of both TST antigen solutions, practitioners and institutions should continue to prioritize their use of existing stock and employ alternatives to TST screening for TB.

Alternatives to TST screening include the use of IGRA blood tests or deferring routine testing of those at low risk of having been exposed to TB. 

Additionally, facilities and institutions are encouraged to review and modify public health rules, regulations, or policies governing TST screening, if needed. 

The following information may be helpful to those facilities and institutions using a priority strategy approach based on relative TB risks.

The highest priority persons for testing include[iv]:

1) persons who are contacts to infectious cases

2) persons being evaluated for suspected active TB

3) persons at increased risk for tuberculosis due to medical conditions*

4) persons recently arrived from high TB incidence countries

 

*Human immunodeficiency virus (HIV)-positive persons, fibrotic changes on chest radiograph consistent with prior TB, patients with organ transplants and other immunosuppressed patients (receiving the equivalent of _15 mg/d of prednisone for 1 month or more or TNF-α antagonist), diabetes mellitus, silicosis, head, neck, or lung cancer, hematologic or reticuloendothelial disease such as Hodgkin’s disease or leukemia, end stage renal disease, intestinal bypass or gastrectomy, chronic malabsorption syndrome, low body weight (i.e., 10% or more below ideal for the given population)

A screening questionnaire to determine TB infection risk status is shown below.

This questionnaire can be used by clinical staff as well as program staff at schools, jails, residential treatment centers and other locations that have continued to require mandatory TST screening of employees, student or clients.

 

Screening to Identify individuals at High Risk for TB Infection or Diseaseii

Yes

No

Prior history of a positive test for TB (PPD, IGRA, sputum, CXR)

 

 

Recent close contact with someone with infectious TB disease

 

 

Foreign-born from (or travel* to/in) a high-prevalence area (e.g., Africa, Asia, Eastern Europe, or Central or South America)

 

 

Fibrotic changes on a prior chest x-ray suggesting inactive or past TB disease

 

 

HIV/AIDS

 

 

Organ transplant recipient

 

 

Immunosuppressed (equivalent of > 15 mg/day of prednisone for >1 month or TNF-α antagonist)

 

 

History of illicit drug use

 

 

Resident, employee, or volunteer in a high-risk congregate setting (e.g., correctional facilities, nursing homes, homeless shelters, hospitals, and other health care facilities)

 

 

Medical condition associated with increased risk of progressing to TB disease if

infected [e.g., diabetes mellitus, silicosis, head, neck, or lung cancer, hematologic or reticuloendothelial disease such as Hodgkin’s disease or leukemia, end stage renal disease, intestinal bypass or gastrectomy, chronic malabsorption syndrome, low body weight (i.e., 10% or more below ideal for the given population)]

 

 

 

If a person answers yes to any of these questions, and is a candidate for treatment of LTBI, then he should be further screened with one of the available tuberculin skin tests or IGRA blood tests based on availability of the product or laboratory services, in accordance with current guidance.

For persons who do not meet any of the above criteria, further LTBI testing should be deferred until such time that adequate supplies of TST supplies are available.

It is important to remember that screening for symptoms of active TB disease should also be done for patients at high risk and before initiating medical therapy for LTBI.

The following symptom screening questionnaire can be used:

Signs and Symptoms of TB Disease:

Does the individual now have:

Yes

No

Cough lasting 3 weeks or longer?

 

 

Coughing up blood?

 

 

Chest pain?

 

 

Night sweats (drenching)?

 

 

Difficulty breathing?

 

 

Hoarseness and/or trouble swallowing?

 

 

Persistent fever and/or chills?

 

 

Persistent fatigue?

 

 

Persistent loss of appetite?

 

 

Weight loss (without dieting)?

 

 

A chest radiograph and other diagnostic assessment should be done as clinically indicated for anyone with a history of active TB or symptoms suggestive of TB. Chest radiographs should also be done on asymptomatic persons with past or current documented positive TST or IGRA tests, unless an earlier CXR report can be documented.

The matrix below provides an algorithm for evaluating individuals for LTBI or TB disease[v]:

Signs or symptoms of TB Disease?

Documented previous positive PPD?

Documented negative PPD in past 12 months?

Yes answer to high risk screening questionnaire?

Action

Yes

 

 

 

Notify physician immediately

No

Yes

 

 

Educate about TB

Recommend treatment for LTBI if not previously treated[vi]

No

No

Yes

 

Educate about TB

No

No

No

Yes

Educate about TB

Screen for LTBI with PPD or IGRA

No

No

No

No

Educate about TB

Defer LTBI screening at this time

Please see the following link for more information. 

http://emergency.cdc.gov/HAN/han00355.asp Exit Disclaimer: You Are Leaving www.ihs.gov

References are listed below.

For Questions or comments, please email Dr. Michael Bartholomew, Michael.Bartholomew@ihs.gov.

Thank you for your review and attention to this important Public Health matter.

Susan V. Karol, MD, FACS

Chief Medical Officer of the Indian Health Service
Member of the Tuscarora Indian Nation
CAPT, USPHS
Susan.karol@ihs.gov
301-443-1083


References:

 

[i] CDC Health Alert Network #355. Available at:  http://emergency.cdc.gov/HAN/han00355.asp Exit Disclaimer: You Are Leaving www.ihs.gov

[ii] Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(RR-6). Available at: http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf Exit Disclaimer: You Are Leaving www.ihs.gov

[iv] NY State DOH Bureau of TB Control, Update to 3/25/2013 Health Advisory: Shortage of Purified Protein Derivative (PPD) for Tuberculin Skin Testing available at: http://www2.monroecounty.gov/files/health/NYSDOH%20Guidance%20on%20PPD%20Shortage%204-15-13.pdf Exit Disclaimer: You Are Leaving www.ihs.gov

[v] Adapted from State of Tennessee Department of Mental Health and Substance Abuse Services, Division of Substance Abuse Services Tuberculosis (TB) Symptom Screening Tool available at: http://tn.gov/mental/A&D/TB_training/TB_SymptomScreeningTool.pdf Exit Disclaimer: You Are Leaving www.ihs.gov

[vi] CDC. MMWR, December 9, 2011 / 60(48);1650-1653. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm Exit Disclaimer: You Are Leaving www.ihs.gov

This website may require you to download plug-ins to view all content.

usa.gov link   Accessibility · Disclaimer · FAQs · Website Privacy Policy · Plain Writing Act · Freedom of Information Act · HIPAA · No Fear · Glossary · Contact

Indian Health Service (HQ) - The Reyes Building, 801 Thompson Avenue, Ste. 400 - Rockville, MD 20852